SCHEMBL2458098

SCHEMBL2458098

CC1(C)CC2CC(C)(CN2S(=O)(=O)c2cc(Cl)ccc2Cl)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.56
▸ LMNA P02545 3/20 0.56
▸ TSHR P16473 3/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HTT P42858 2/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ GAA P10253 3/20 0.55
▸ HPGD P15428 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ ACHE P22303 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ ALOX15 P16050 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ GALR3 O60755 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ AVPR1A P37288 3/20 0.42
▸ AVPR2 P30518 2/20 0.42
▸ HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12309247 0.90 ALDH1A1 (0.56) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309384 0.89 ALDH1A1 (0.55) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309234 0.85 ALDH1A1 (0.58) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309245 0.82 ALDH1A1 (0.76) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309343 0.82 ALDH1A1 (0.55) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL2462776 0.81 ALDH1A1 (0.58) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309291 0.80 ALDH1A1 (0.57) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309230 0.79 ALDH1A1 (0.52) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309287 0.79 ALDH1A1 (0.71) ALDH1A1LMNATSHRKMT2AHTT
SCHEMBL12309233 0.79 ALDH1A1 (0.61) ALDH1A1LMNATSHRKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8466149-B2 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I MERCK SHARP & DOHME CORP. (US) 2013-06-18 — — US claimed
US-20110237559-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2011-09-29 — — US claimed
EP-2188293-A1 6-SUBSTITUTED SULFONYL AZABICYCLOÝ3.2.1¨OCTANES USEFUL TO INHIBIT 11 -HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2010-05-26 — — EP claimed
WO-2009023181-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11β-HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2009-02-19 — — WO claimed
EP-2188293-B1 6-SUBSTITUTED SULFONYL AZABICYCLOÝ3.2.1¨OCTANES USEFUL TO INHIBIT 11 -HYDROXYSTEROID DEHYDROGENASE TYPE-1 MERCK SHARP & DOHME (US) 2019-05-01 — — EP disclosed
US-8466149-B2 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I MERCK SHARP & DOHME CORP. (US) 2013-06-18 — — US disclosed
US-8466149-B2 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I MERCK SHARP & DOHME CORP. (US) 2013-06-18 — — US disclosed
US-8466149-B2 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I MERCK SHARP & DOHME CORP. (US) 2013-06-18 — — US disclosed
US-20110237559-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2011-09-29 — — US disclosed
US-20110237559-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2011-09-29 — — US disclosed
US-20110237559-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2011-09-29 — — US disclosed
WO-2009023181-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11β-HYDROXYSTEROID DEHYDROGENASE TYPE-1 SCHERING CORPORATION (US) 2009-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237559-A1 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 HSD17B1, HSD11B1, HSD17B11 ALDH1A1 29/4885LMNA 3130/4885TSHR 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback